Arix Bioscience
Arix Bioscience, a leading life sciences company headquartered in Great Britain, focuses on advancing innovative therapies in the biotechnology sector. Founded in 2013, Arix has established itself as a key player in the industry, with a strong emphasis on developing and commercialising breakthrough treatments across various therapeutic areas, including oncology and rare diseases.
The company is renowned for its unique approach to building and supporting a diverse portfolio of life science companies, leveraging its deep expertise and extensive network. Arix Bioscience's commitment to fostering innovation has positioned it as a prominent venture capital firm, recognised for its strategic investments and successful partnerships. With a robust pipeline of core products and a reputation for excellence, Arix continues to make significant strides in transforming healthcare and improving patient outcomes.
-3 vs industry average
Arix Bioscience’s score of 26 is lower than 47% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Arix Bioscience?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Research Services has typical carbon intensity
Industry performance
The Research Services industry has increased its overall emissions by 17% since 2019
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Arix Bioscience's reported carbon emissions
In 2022, Arix Bioscience, headquartered in Great Britain, reported total carbon emissions of approximately 12,300 kg CO2e, comprising 3,680 kg CO2e from Scope 1, 4,410 kg CO2e from Scope 2, and 5,210 kg CO2e from Scope 3 emissions. This data reflects a commitment to transparency in their environmental impact. Arix Bioscience has set ambitious climate targets, aiming to achieve net-zero emissions by 2050 or sooner, with a goal to reduce emissions by over 90% by that time. Additionally, they are targeting a 40% reduction in carbon emissions by 2025 compared to a 2019 baseline, normalised to occupied areas. These initiatives demonstrate Arix's proactive approach to addressing climate change and reducing their carbon footprint across all scopes of emissions. The company has disclosed emissions data for all relevant scopes, showcasing their commitment to comprehensive climate reporting and accountability.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Arix Bioscience’s Climate Goals (2030 & 2050)
2 goals2050
90% reduction in all scopes
Target Two: Known as our ‘long-term target’, we need to operate as a fully Net-Zero business by 2050 or sooner. This involves removing more…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Arix Bioscience
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project